

## NCIC CLINICAL TRIALS GROUP

**GASTROINTESTINAL**DISEASE SITE COMMITTEE MEETING  
AGENDA**OPEN SESSION**

Venue: Hilton Montreal Bonaventure, Montreal  
 Room: Outremont  
 Date: Sunday, April 30<sup>th</sup>, 2006  
 Time: 8:30 am – 2:45 pm  
 Chair: Dr. Malcolm Moore

---

8:30 am	<b>WELCOME AND INTRODUCTION</b>	Dr. M. Moore
8:35 am	<b>CLOSED TRIALS</b>	
	<b>CO.19:</b> A Phase III Randomized Double-Blind Placebo-Controlled Trial of FOLFOX with or without PTK 787after Curative Resection for Patients with Stage III Colon Cancer	Dr. M. Moore
	<b>PA.4:</b> A Phase III, Multi-centre, Double-Blind, Placebo-Controlled Study of AMG 706 plus Gemcitabine and Erlotinib in Patients with Unresectable Locally Advanced or Metastatic Pancreatic Cancer	Dr. M. Moore
	<b>CO.16 (MRC CR07):</b> Pathology-guided Treatment in Rectal Cancer - A randomised trial comparing pre-operative radiotherapy and selective post-operative chemoradiotherapy in rectal cancer	Dr. J. Couture
	<b>CO.17:</b> A Phase III Randomized Study of Cetuximab (Erbix <sup>TM</sup> , C225) and Best Supportive Care versus Best Supportive Care in Patients with Pretreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Positive Colorectal Carcinoma	Dr. D. Jonker
	<b>PAC.1 (SWOG-S0205):</b> A Randomized Placebo Controlled Study of Cetuximab plus Gemcitabine in Patients with Locally Advanced, Unresectable or Metastatic Pancreatic Cancer	Dr. Ralph Wong
	<b>PAC.2 (ECOG-E4201):</b> A Randomized Phase III Study of Gemcitabine in Combination with Radiation Therapy versus Gemcitabine Alone in Patients with Localized, Unresectable Pancreatic Cancer	Dr. J. Biagi
9:00 am	<b>ACTIVE TRIALS</b>	
	<b>ES.2 (TROG 03.01):</b> A Randomised Phase III Study in Advanced Oesophageal Cancer to Compare Quality of Life and palliation of Dysphagia in Patients Treated with Radiotherapy versus Chemo-Radiotherapy	Dr. Rebecca Wong
	<b>PA.2 (ESPAC-3):</b> Adjuvant Chemotherapies in Resectable Pancreatic Cancer	Dr. M. Moore

9:15 am **ENDORSED CTSU TRIALS**

**GAC.1** (CALGB-80101): A Phase III Trial of Adjuvant Chemoradiation After Resection of Gastric Or Gastroesophageal Adenocarcinoma

Dr. G. Bjarnason

**CRC.2** (NCCTG N0147): A Randomized Phase III Trial of Irinotecan (CPT-11) and/or Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer

Dr. S. Gill

**CRC.3** (ECOG E5202): A Randomized Phase III Study Comparing 5-FU Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers.

Dr. C. Butts

**CRC.4** (ECOG E5204): Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation.

Dr. J. Couture

9:45 am **UPDATE - ENDORSING AND PARTICIPATING IN CTSU TRIALS**

Dr. C. O'Callaghan

9:55 am **TRIALS IN DEVELOPMENT**

**CO.18**: A Phase II Study of AZD2171 and Capecitabine versus Capecitabine Alone as 1<sup>st</sup> Line Therapy in Patients with Metastatic Colorectal Cancer

Dr. C. Cripps

**BI.1**: A Phase III Study of Gemcitabine Plus Capecitabine (GEMCAP) versus Gemcitabine Alone in Advanced Biliary Cancer

Dr. J. Knox

**CO.20**: A Phase III Randomized Study of BMS582664 and Cetuximab (Erbix<sup>TM</sup>) versus Cetuximab in Patients with Pretreated Metastatic Colorectal Carcinoma

Dr. L. Siu

10:30 am **REFRESHMENT BREAK**11:00 am **DISCUSSION – CETUXIMAB IN CANADA**

Dr. M. Moore

11:15 am **DISEASE ORIENTED WORKING GROUP REPORTS / NEW TRIALS****IND**

Dr. Ralph Wong

**Colon DOG**

Dr. D. Jonker

12:00 pm **LUNCH**1:00 pm **DISEASE ORIENTED GROUP REPORTS / NEW TRIALS (CONTINUED)****Rectal DOG**

Dr. J. Couture

**Esophageal DOG**

Dr. Rebecca Wong

	<b>Pancreas DOG</b>	Dr. M. Moore
2:15 pm	<b>GI INTERGROUP UPDATE</b>	Dr. M. Moore
2:30 pm	<b>CLOSING REMARKS &amp; ADJOURNMENT</b>	Dr. M. Moore
2:45 pm	<b>CLOSED SESSION: GI EXECUTIVE MEETING</b>	Dr. M. Moore